Recent Advancement in the Treatment of Cardiovascular Diseases: Conventional Therapy to Nanotechnology.
Cardiovascular disease (CVD), accounting around 30% of deaths worldwide, collectively comprised of disorders affecting the heart and blood vessels as well as their associated adverse conditions. Despite outstanding progress in the area of the treatments of CVDs, significant challenges remain in designing of efficient delivery systems for myocardial therapy. Moreover, current therapy for CVDs is limited due to various clinical complications such as systemic toxicity, stent thrombosis, etc. Molecular and nanotechnology approaches provide the tools to explore such frontiers of biomedical science at the cellular level and thus offer unique features for potential application in the field of cardiac therapy. In this review, recent advances in CVD related risk factors, chronic inflammation, and their therapeutic modalities such as stem cell therapy, gene delivery, tissue factor (TF) inhibitors, miRNAs, leukotriene modifiers, thrombolytic agents etc., in modern molecular aspects are discussed. Moreover, nanoparticle based drug delivery, nanocarriers as molecular imaging, and the various challenges of myocardial tissue engineering aspects have been summarized. All these aspects may provide additional therapeutic substitutes in clinical trials for the registration of new drugs.
Sudhanshu S
SS
Behera
Krishna
K
Pramanik
Department of Internal Medicine, University of Iowa, Iowa city, 52242, USA. manaskumarnayakbiotech@gmail.com.
Manasa K
MK
Nayak
D002318:Cardiovascular Diseases / Q000628:therapy*; D004337:Drug Carriers / Q000737:chemistry; D006801:Humans; D050997:Nanomedicine; D053758:Nanoparticles / Q000737:chemistry; D023822:Tissue Engineering
D004337:Drug Carriers